EMA (European Medicines Agency) Guidelines

The Role of CHMP in Clinical Trials Approval Under EMA: A Regulatory Insight

Posted on digi By digi

The Committee for Medicinal Products for Human Use (CHMP) is the EMA’s key scientific body responsible for the evaluation of human medicines. It is composed of experts from EU member states, plus Iceland and Norway, with additional co-opted specialists when required. The CHMP ensures that decisions on human medicines, including clinical trials, are based on solid scientific evidence and consistent regulatory interpretation.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Scientific Advice Procedure: A Strategic Guide for Regulatory Success in the EU

Posted on digi By digi

Scientific Advice is a voluntary, non-binding procedure through which the EMA provides guidance to sponsors on the best methods and practices for generating data during drug development. This guidance helps ensure that the resulting data meets EU regulatory expectations, reducing the risk of rejection or delays during the marketing authorization application (MAA) phase.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Adaptive Pathways Strategy by EMA: A Progressive Approach to Drug Access

Posted on digi By digi

Originally launched as a pilot in 2014, the Adaptive Pathways initiative (formerly known as adaptive licensing) is a regulatory pathway designed to enable early and progressive access to new medicines. It allows for initial approval in a restricted population based on early clinical data, with expansion to broader populations as additional evidence becomes available.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Risk Management Plans (RMPs): A Guide to EU Pharmacovigilance Compliance

Posted on digi By digi

A Risk Management Plan is a detailed document submitted to EMA that outlines known and potential risks of a medicine, strategies for monitoring, and risk minimization measures. RMPs are essential for maintaining the balance between therapeutic benefits and risks, especially for newly authorized products or products with emerging safety concerns.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Data Transparency and Clinical Trial Reports to the EMA: A Compliance Guide

Posted on digi By digi

The EMA believes that making clinical trial results publicly accessible enhances scientific discourse, supports healthcare decision-making, and prevents duplication of efforts. By enforcing transparency, the agency also encourages good clinical practice and ethical conduct in pharmaceutical development.
Click to read the full article.

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines